المؤلفون: Farrukh Vohidov (2072296), Jannik N. Andersen (199563), Kyriakos D. Economides (10332160), Michail V. Shipitsin (10332163), Olga Burenkova (10332166), James C. Ackley (10332169), Bhavatarini Vangamudi (1313319), Hung V.-T. Nguyen (2885066), Nolan M. Gallagher (1795861), Peyton Shieh (1586818), Matthew R. Golder (1678135), Jenny Liu (647696), William K. Dahlberg (2188987), Deborah J. C. Ehrlich (10332172), Julie Kim (10332175), Samantha L. Kristufek (10332178), Sung Jin Huh (2401033), Allison M. Neenan (10332181), Joelle Baddour (10332184), Sattanathan Paramasivan (10332187), Elisa de Stanchina (153061), Gaurab KC (10332190), David J. Turnquist (10332193), Jennifer K. Saucier-Sawyer (10332196), Paul W. Kopesky (10332199), Samantha W. Brady (5211746), Michael J. Jessel (10332202), Lawrence A. Reiter (335508), Donald E. Chickering (4847407), Jeremiah A. Johnson (1316577), Peter Blume-Jensen (199585)

مصطلحات موضوعية: Biochemistry, Medicine, Pharmacology, Biotechnology, Immunology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, drug development, novel BETi prodrugs, protein inhibitors, prodrug design, prodrug activation kinetics, vivo tumor pharmacokinetics, Such approaches, traceless linkers, tissues offer, Superior Efficacy, BET Inhibitor Bottlebrush Prodrugs, dose-limiting toxicities, antitumor efficacies, syngeneic triple-negative breast ca., trial-and-error design, TI, Systemic Toxicities Prodrugs, prodrug platform

Relation: https://figshare.com/articles/journal_contribution/Design_of_BET_Inhibitor_Bottlebrush_Prodrugs_with_Superior_Efficacy_and_Devoid_of_Systemic_Toxicities/14251084

الاتاحة: https://doi.org/10.1021/jacs.1c00312.s001